BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Nuplazid (Pimavanserin) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Nuplazid (Pimavanserin)\, from ClinicalTr
 ials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05895513-854@assetmemo.bio
DTSTAMP:20261121T005649Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Nuplazid (Pimavanserin): Phase 2 readout est. (NCT05895513)
DESCRIPTION:Nuplazid (Pimavanserin)\, phase 2.\nStudy: Pimavanserin and Agg
 ression and Social Cognition.\nEstimated primary completion: January 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/pimavanserin#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05895513
URL:https://assetmemo.bio/drug/pimavanserin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06455293-854@assetmemo.bio
DTSTAMP:20261121T005649Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Nuplazid (Pimavanserin): Phase 2 readout est. (NCT06455293)
DESCRIPTION:Nuplazid (Pimavanserin)\, phase 2.\nStudy: Psilocybin Therapy f
 or Depression in Parkinson's Disease\nEstimated primary completion: June 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/pimavanserin#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0645529
 3
URL:https://assetmemo.bio/drug/pimavanserin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05357612-854@assetmemo.bio
DTSTAMP:20261121T005649Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Nuplazid (Pimavanserin): Phase 4 readout est. (NCT05357612)
DESCRIPTION:Nuplazid (Pimavanserin)\, phase 4\, Parkinson's Disease Psychos
 is.\nStudy: Characterization of the Serotonin 2A Receptor Selective PET Tr
 acer [18F]MH.MZ in Patients With Neurodegenerative Diseases\nEstimated pri
 mary completion: June 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/pimavanserin#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05357612
URL:https://assetmemo.bio/drug/pimavanserin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05441280-854@assetmemo.bio
DTSTAMP:20261121T005649Z
DTSTART;VALUE=DATE:20270712
DTEND;VALUE=DATE:20270713
SUMMARY:Nuplazid (Pimavanserin): Phase 2 readout est. (NCT05441280)
DESCRIPTION:Nuplazid (Pimavanserin)\, phase 2.\nStudy: Pimavanserin for Ins
 omnia in Veterans With PTSD\nEstimated primary completion: 12 July 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/pimavanserin#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT05441280
URL:https://assetmemo.bio/drug/pimavanserin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04373317-854@assetmemo.bio
DTSTAMP:20261121T005649Z
DTSTART;VALUE=DATE:20271024
DTEND;VALUE=DATE:20271025
SUMMARY:Nuplazid (Pimavanserin): Phase 4 readout est. (NCT04373317)
DESCRIPTION:Nuplazid (Pimavanserin)\, phase 4\, Parkinson's Disease Psychos
 is.\nStudy: Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psych
 osis\nEstimated primary completion: 24 October 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/pimavanserin#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT04373317
URL:https://assetmemo.bio/drug/pimavanserin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05999240-854@assetmemo.bio
DTSTAMP:20261121T005649Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Nuplazid (Pimavanserin): Phase 2 readout est. (NCT05999240)
DESCRIPTION:Nuplazid (Pimavanserin)\, phase 2.\nStudy: Pimavanserin for Rig
 id-compulsive Symptoms in Autism Spectrum Disorder\nEstimated primary comp
 letion: 31 October 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/pimavanserin#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05999240
URL:https://assetmemo.bio/drug/pimavanserin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07610135-854@assetmemo.bio
DTSTAMP:20261121T005649Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Nuplazid (Pimavanserin): Phase 1/2 readout est. (NCT07610135)
DESCRIPTION:Nuplazid (Pimavanserin)\, phase 1/2.\nStudy: Psilocybin Efficac
 y With or Without Pimavanserin Pretreatment\nEstimated primary completion:
  June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pimavanse
 rin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07610135
URL:https://assetmemo.bio/drug/pimavanserin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06592833-854@assetmemo.bio
DTSTAMP:20261121T005649Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Nuplazid (Pimavanserin): Phase 2 readout est. (NCT06592833)
DESCRIPTION:Nuplazid (Pimavanserin)\, phase 2.\nStudy: Psilocybin With Pima
 vanserin Compared to Psilocybin Alone for the Treatment of Major Depressiv
 e Disorder\nEstimated primary completion: March 2029. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/pimavanserin#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06592833
URL:https://assetmemo.bio/drug/pimavanserin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07895134-854@assetmemo.bio
DTSTAMP:20261121T005649Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Nuplazid (Pimavanserin): Phase 2 readout est. (NCT07895134)
DESCRIPTION:Nuplazid (Pimavanserin)\, phase 2.\nStudy: Psilocybin for Depre
 ssion in Veterans\nEstimated primary completion: 31 December 2031. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/pimavanserin#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07895134
URL:https://assetmemo.bio/drug/pimavanserin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
